TRI-SPECIFIC KILLER ENGAGER

Clinical trials for TRI-SPECIFIC KILLER ENGAGER explained in plain language.

Never miss a new study

Get alerted when new TRI-SPECIFIC KILLER ENGAGER trials appear

Sign up with your email to follow new studies for TRI-SPECIFIC KILLER ENGAGER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New 'killer engager' drug aims to unleash immune cells on stubborn tumors

Disease control Recruiting now

This early-phase study tests a new drug called GTB-5550 in adults with advanced solid tumors that have not responded to prior treatments. The drug is designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. The main goal is to find the …

Matched conditions: TRI-SPECIFIC KILLER ENGAGER

Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control

Last updated May 13, 2026 16:02 UTC

TRI-SPECIFIC KILLER ENGAGER

Get alerted when new TRI-SPECIFIC KILLER ENGAGER trials appear

New 'killer engager' drug aims to unleash immune cells on stubborn tumors